Track topics on Twitter Track topics that are important to you
Ocugen has closed a $7.5 million round of Series B funding to support the advancement of potential sight-saving ophthalmology products into clinical trials, the company announced in a press release. Led by the Turkish pharmaceutical company Abdi Ibrahim and the JSC Lancaster Group from Kazakhstan, investors also included Frank Leo and John Zhang, PhD.
Original Article: Ocugen to advance pipeline with $7.5 million in Series B financingNEXT ARTICLE
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...